SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Nvidia Develops New Location-Verification Technology for AI Chips 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Chinese pharmaceutical giant WuXi AppTec (SS:603259) expects its first-half net profit to more than double, driven by soaring demand for its contract research and manufacturing services. The company announced on Thursday that net profit attributable for the six months ending June 30 is projected to jump 101.9% year-over-year, reaching 8.56 billion yuan (approximately $1.19 billion). This surge includes a significant one-time gain from the partial divestment of its subsidiary, WuXi XDC Cayman.
Excluding one-off items, adjusted net profit is forecast to rise 44.4% to 6.31 billion yuan, underscoring strong performance in its integrated CRDMO (Contract Research, Development, and Manufacturing Organization) business model. The firm said that increasing global demand for end-to-end drug development solutions has been a key growth driver.
Total revenue for the first half of 2025 is expected to grow 20.6% year-over-year, reaching approximately 20.8 billion yuan. Revenue from core operations alone rose by 24.2%, reflecting enhanced operational efficiency and expanded manufacturing capacity.
WuXi AppTec’s continued investment in innovation, infrastructure, and client-centric services is positioning the company as a global leader in pharmaceutical outsourcing. With the biotech and pharmaceutical sectors increasingly relying on external partners to accelerate drug development pipelines, WuXi AppTec appears well-placed to capitalize on this structural shift.
The company’s impressive growth trajectory reinforces confidence in its CRDMO strategy, which offers integrated solutions across research, development, and manufacturing phases. As global demand for efficient and scalable pharmaceutical services rises, WuXi AppTec’s performance signals strong momentum heading into the second half of the year.
